IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03333A
IN2014CN03333A IN3333CHN2014A IN2014CN03333A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A IN 3333CHN2014 A IN3333CHN2014 A IN 3333CHN2014A IN 2014CN03333 A IN2014CN03333 A IN 2014CN03333A
Authority
IN
India
Prior art keywords
shk
potassium channel
inhibiting agent
modified
obesity
Prior art date
Application number
Inventor
George K Chandy
Sanjeev Kumar Upadhayay
Ping H Wang
Paolo Sassone Corsi
Kristin Lynn Eckel Mahan
Shawn Iadonato
Joseph Mukergee
Reza M Mirbolooki
Original Assignee
Univ California
Kineta One Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kineta One Llc filed Critical Univ California
Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Activation of brown adipose tissue treatment of obesity and/or treatment of obesity related disorders in human or non human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK 186.
IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
IN2014CN03333A true IN2014CN03333A (en) 2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3333CHN2014 IN2014CN03333A (en) 2011-10-03 2012-10-02

Country Status (16)

Country Link
US (2) US20150072940A1 (en)
EP (1) EP2763702A4 (en)
JP (1) JP2014531469A (en)
KR (1) KR20140108518A (en)
CN (1) CN103987408A (en)
AU (1) AU2012318736A1 (en)
BR (1) BR112014008065A2 (en)
CA (1) CA2850357A1 (en)
HK (1) HK1201048A1 (en)
IL (1) IL231873A0 (en)
IN (1) IN2014CN03333A (en)
MX (1) MX2014004029A (en)
RU (1) RU2014117558A (en)
SG (1) SG11201401193XA (en)
TW (1) TW201321403A (en)
WO (1) WO2013052507A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294124B2 (en) * 2004-10-07 2012-02-23 Bachem Biosciences, Inc. Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
TWI535455B (en) 2011-06-06 2016-06-01 奇尼塔一有限責任公司 Shk-based pharmaceutical compositions and methods of manufacturing and using the same
WO2013052507A1 (en) 2011-10-03 2013-04-11 The Regents Of The University Of California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS
JP7211704B2 (en) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス A tablet containing a GLP-1 agonist and an enteric coating
TWI698438B (en) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Kv1.3 inhibitors and their medical application
TWI701249B (en) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Kv1.3 inhibitors and their medical application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
WO1999013895A1 (en) * 1997-09-17 1999-03-25 University Of Florida Polypeptide compositions that inhibit potassium channel activity and uses therefor
JP3207823B2 (en) 1999-04-28 2001-09-10 リノール油脂株式会社 Brown fat enhancer containing conjugated linoleic acid as active ingredient
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
AU2005294124B2 (en) * 2004-10-07 2012-02-23 Bachem Biosciences, Inc. Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
BRPI0616995A2 (en) * 2005-08-17 2011-07-05 Solvay Pharm Gmbh pharmaceutical composition, and use of kv1.3 potassium channel inhibitor in drug preparation
TW201026708A (en) * 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2013052507A1 (en) 2011-10-03 2013-04-11 The Regents Of The University Of California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Also Published As

Publication number Publication date
KR20140108518A (en) 2014-09-11
CA2850357A1 (en) 2013-04-11
RU2014117558A (en) 2015-11-10
US20150072940A1 (en) 2015-03-12
EP2763702A1 (en) 2014-08-13
EP2763702A4 (en) 2015-04-15
MX2014004029A (en) 2014-08-01
CN103987408A (en) 2014-08-13
US20170095530A1 (en) 2017-04-06
BR112014008065A2 (en) 2019-09-24
IL231873A0 (en) 2014-05-28
TW201321403A (en) 2013-06-01
JP2014531469A (en) 2014-11-27
WO2013052507A1 (en) 2013-04-11
AU2012318736A1 (en) 2014-05-22
SG11201401193XA (en) 2014-05-29
HK1201048A1 (en) 2015-08-21
US9878006B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX344238B (en) Tetrazole compounds and methods of making and using same.
IN2014CN03333A (en)
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX2013007189A (en) Methods and compositions suitable for managing blood glucose in animals.
MX2013013809A (en) Expandable devices coated with a paclitaxel composition.
IN2015DN00376A (en)
BR112013000433A2 (en) diagnosis and treatment of breast cancer
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
BR112014001170A2 (en) catheter, especially a permanent catheter, for treating functional problems and / or bladder and / or prostate disease
MX364220B (en) Methods of treating fibrosis.
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
MX2013008175A (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof.
MX2014001393A (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one.
MX2016000220A (en) Regulation of glucose metabolism using anti-cgrp antibodies.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2013013808A (en) Expandable devices coated with a rapamycin composition.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
MX364643B (en) Treatment of type 2 diabetes with fty720.
UA61499U (en) massage mat